

FACSIMILE TRANSMISSION SHEET

D. PETER HOCHBERG CO., L.P.A.
ATTORNEYS AT LAW
1940 EAST 6TH STREET
CLEVELAND, OHIO 44114

FAX RECEIVED

JUN 10 2002

GROUP 1600

Telephone: (216) 771-3800 / Facsimile: (216) 771-3804 / e-mail: dphochberg@aol.com

TO: Ms. Isis Ghali FAX NO: (703) 872-9306
FROM: Peter Hochberg DATE: June 7, 2002
NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 3

MESSAGE Re: U.S.S. No. 09/720,287
Filed: May 10, 2001
Our Ref: R00208US (#90568)

Pursuant to our discussion today, I
have attached the page from the application
with the original claims.

*****PRIVILEGED AND CONFIDENTIAL*****

This communication is intended only for the use of the named addressee(s) and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via the U.S. Postal Service. Thank you.

FAX RECEIVED

JUN 10 2002

GROUP 1600

- 8 -

CLAIMS

1. Transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients which is attached to said backing layer and prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino-containing polymer.

~~OFFICIAL~~

2. Transdermal therapeutic system according to Claim 1, characterized in that the crystallization inhibitor is selected from polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, in particular in a molar ratio of 1:2:1, polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, polyamines and polyglucosamines.

3. Transdermal therapeutic system according to either of Claims 1 and 2, characterized in that the reservoir comprises one or more crystallization inhibitors in a proportion of from 0.05-30% by weight.

4. Transdermal therapeutic system according to one or more of Claims 1 - 3, characterized in that the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, preferably from 1:3 to 1:7, and in an overall concentration of up to 25% by weight.

5. Transdermal therapeutic system according to one or more of Claims 1 - 4, characterized in that the reservoir includes a constituent from the group of ageing inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizer being used in a concentration of 0-5% by weight

- 9 -

and the ageing inhibitor in a concentration of 0.1-2% by weight.

6. Transdermal therapeutic system according to one or more of Claims 1 - 5, characterized in that the pressure-sensitive adhesive is a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive or a UV-crosslinkable adhesive.

7. Transdermal therapeutic system according to one or more of Claims 1 - 6, characterized in that the reservoir consists of two or more layers.

8. Transdermal therapeutic system according to one or more of Claims 1 - 7, characterized in that the reservoir has a layer thickness of 0.02 mm-0.500 mm, preferably 0.030-0.200 mm.

9. Transdermal therapeutic system according to one or more of Claims 1 - 8, characterized in that the reservoir is provided with an additional pressure-sensitive adhesive layer and/or with a pressure-sensitive adhesive margin.

10. Use of the transdermal therapeutic system corresponding to one or more of Claims 1-9 for therapeutic applications in human medicine.